{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458433649
| image =  
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = o
| target = {{link-en|CD3受体|CD3 (immunology)|CD3ε}}
<!--Clinical data -->
| tradename =  
| Drugs.com = {{drugs.com|CDI|muromonab-cd3}}
| MedlinePlus = a605011
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Rx
| routes_of_administration = [[靜脈注射|靜脈注射]]
<!--Pharmacokinetic data -->
| bioavailability = N/A
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!--Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 140608-64-6
| ATC_prefix = L04
| ATC_suffix = AA02
| PubChem =  
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00075
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = JGA39ICE2V
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201608
<!--Chemical data -->
| C=6460 | H=9946 | N=1720 | O=2043 | S=56
}}

'''莫罗单抗-CD3'''（Muromonab-CD3，[[杨森制药|杨森制药]]以商品名'''Orthoclone OKT3'''出售）是降低接受器官移植病人[[移植排斥|急性排斥反应]]的[[免疫抑制剂|免疫抑制剂]]。<ref name="pmid12588325">{{cite journal |vauthors=Midtvedt K, Fauchald P, Lien B, etal |title=Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection |journal=Clinical Transplantation |volume=17 |issue=1 |pages=69–74 |date=February 2003 |pmid=12588325 |doi=10.1034/j.1399-0012.2003.02105.x |s2cid=8677441 }}</ref><ref name="Mutschler">{{cite book|last=Mutschler|first=Ernst|author2=Gerd Geisslinger |author3=Heyo K. Kroemer |author4=Monika Schäfer-Korting |title=Arzneimittelwirkungen|publisher=Wissenschaftliche Verlagsgesellschaft|location=Stuttgart|date=2001|edition=8|page=937|isbn=3-8047-1763-2|language=de}}</ref>本药是针对T细胞表面{{link-en|CD3受体|CD3 (immunology)}}的[[单克隆抗体|单克隆抗体]]。<ref>{{cite web|url= http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6889|title= muromonab-CD3|date= |website= Guide to Pharmacology|publisher= IUPHAR/BPS|access-date= 21 August 2015}}</ref>本药是首个[[醫療產品法律規範|获准人类临床运用]]的单抗。<ref name="Mutschler" />

== 历史 ==

莫罗单抗-CD3于1985年由[[美国食品药品监督管理局|美国食品药品监督管理局]]批准，<ref name="Smith">{{Cite journal 
| pmid = 9188368 
| year = 1996 
| last1 = Smith | first1 = S. L. 
| title = Ten years of Orthoclone OKT3 (muromonab-CD3): a review 
| volume = 6 
| issue = 3 
| pages = 109–119; quiz 119–1 
| journal = Journal of Transplant Coordination | doi=10.7182/prtr.1.6.3.8145l3u185493182
}}</ref>是首个允许人用的单抗。本药根据[[欧洲联盟指令|指令]]87/22/EWG在[[欧洲共同体|欧洲共同体]]境内获准，该指令是[[欧洲药品管理局|欧洲药品管理局]]中央审批系统的前身。其审批流程首先通过了{{link-en|人用药委员会|Committee for Medicinal Products for Human Use|专利药品委员会}}（现人用药委员会）评估后由各成员国卫生主管机关批准；以德国为例，保罗·埃尔利希研究所于1988年批准本药。由于本药存在众多副作用、使用量减少、亦有更好耐受性的替代药品，<ref>{{cite journal|last=Mahmud|first=Nadim |author2=Dusko Klipa|author3=Nasimul Ahsan|title=Antibody immunosuppressive therapy in solid-organ transplant Part 1|journal=mAbs|year=2010|volume=2|issue=2|pages=148–156 |doi=10.4161/mabs.2.2.11159 |pmid=20150766 |pmc=2840233 }}</ref>生产厂家于2010年自愿将其撤出美国市场。<ref>{{cite journal|last=Abdi|first=Reza|author2=Spencer Martin|author3=Steven Gabardi|title=Immunosuppressive Strategies in Human Renal Transplantation – Induction Therapy|journal=Nephrology Rounds|year=2009|volume=7|issue=4|url=http://www.nephrologyrounds.org/crus/304-072.pdf|accessdate=11 November 2012}}{{Dead link|date=October 2019 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>

== 适应证 ==

莫罗单抗-CD3获准用于治疗抵抗[[糖皮质激素|糖皮质激素]]{{link-en|异体移植|Allotransplantation|异体}}[[肾移植|肾]]、[[心脏移植|心脏]]、{{link-en|肝移植|liver transplant|肝移植}}急性排异反应。<ref name="DrugsCom">{{cite web|url=https://www.drugs.com/mmx/orthoclone-okt3.html|title=Orthoclone OKT3|work=Professional Drug Information|publisher=Drugs.com|accessdate=3 January 2010}}</ref>本药与{{link-en|巴利昔单抗|Basiliximab}}、{{link-en|达利珠单抗|daclizumab}}不同，未获准用于[[預防醫學|预防]]移植排异；1996年的一篇综述认为本药可安全用于此用途。<ref name="Smith" />

有使用本药治疗{{link-en|T淋巴母细胞白血病／淋巴瘤|T-lymphoblastic leukemia/lymphoma|T细胞急性淋巴母细胞白血病}}的研究。<ref name="pmid7885036">{{cite journal  |vauthors=Gramatzki M, Burger R, Strobel G, etal |title=Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness |journal=Leukemia |volume=9 |issue=3 |pages=382–90 |date=March 1995 |pmid=7885036}}</ref>

== 药物效应动力学与化学 ==
T细胞主要通过[[T细胞受体|T细胞受体]]（TCR）识别抗原。<ref name="Rich2013">{{Cite book |last=Rich |first=Robert |url=https://www.sciencedirect.com/book/9780723436911/clinical-immunology |title=Clinical immunology : principles and practice |publisher=Elsevier |year=2013 |isbn=978-0-7234-3710-9 |edition=4th ed |location=London |oclc=823736017}}</ref>{{rp|160}}。CD3是组成TCR复合体的蛋白之一。<ref name="Rich2013"/>{{rp|166}}TCR-CD3复合体转导抗原信号，使T细胞[[细胞增殖|增殖]]、并攻击抗原。<ref name="Rich2013"/>{{rp|160}}

莫罗单抗-CD3是通过{{link-en|杂交瘤技术|hybridoma technology}}产生的小鼠单克隆IgG2抗体。<ref>{{Cite journal |last=Sgro |first=C. |date=1995-12-20 |title=Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review |url=http://www.sciencedirect.com/science/article/pii/0300483X9503123W |journal=Toxicology |series=Immunotoxicology Papers presented at the Third Summer School in Immunotoxicology |language=en |volume=105 |issue=1 |pages=23–29 |doi=10.1016/0300-483X(95)03123-W |issn=0300-483X}}</ref>该抗体与TCR复合体上的CD3ε链结合，首先诱导T细胞活化，<ref name="Bhorade2009">{{Cite journal |last=Bhorade |first=S. M. |last2=Stern |first2=E. |date=2009-01-15 |title=Immunosuppression for Lung Transplantation |url=https://doi.org/10.1513/pats.200808-096go |journal=Proceedings of the American Thoracic Society |volume=6 |issue=1 |pages=47–53 |doi=10.1513/pats.200808-096go |issn=1546-3222}}</ref>之后清除T细胞表面TCR复合体并导致[[细胞凋亡|细胞凋亡]]。<ref>{{Cite journal |last=Benekli |first=M. |last2=Hahn |first2=T. |last3=Williams |first3=B. T. |last4=Cooper |first4=M. |last5=Roy |first5=H. N. |last6=Wallace |first6=P. |last7=Stewart |first7=C. |last8=Bambach |first8=B. |last9=McCarthy |first9=P. L. |date=2006-09 |title=Muromonab-CD3 (Orthoclone OKT3 ® ), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation |url=https://www.nature.com/articles/1705450 |journal=Bone Marrow Transplantation |language=en |volume=38 |issue=5 |pages=365–370 |doi=10.1038/sj.bmt.1705450 |issn=1476-5365}}</ref>本药以此保护移植器官不受T细胞攻击。<ref name="Mutschler" /><ref name="DrugsCom" />在器官移植诱导治疗时本药每日用药一次，持续七天。<ref name="Bhorade2009"/>

正在研发的新单抗中，使用与本药相同机制的包括：{{link-en|奥昔珠单抗|otelixizumab}}（TRX4）、{{link-en|替利珠单抗|teplizumab}}（hOKT3γ1(Ala-Ala) ）、{{link-en|维西珠单抗|visilizumab}}（暂定商品名Nuvion）。正在研究上述药物用于其他疾病的效果（[[克隆氏症|克隆氏症]]、[[溃疡性结肠炎|溃疡性结肠炎]]、[[1型糖尿病|1型糖尿病]]）。{{link-en|替利珠单抗|teplizumab}}最近的III期临床试验效果“令人失望”，因此其未来并不明朗。<ref>{{cite news |url=http://www.genengnews.com/gen-news-highlights/macrogenics-and-lilly-ponder-future-of-diabetes-mab-after-phase-iii-flop/81244098/ |title=MacroGenics and Lilly Ponder Future of Diabetes mAb after Phase III Flop |date=21 Oct 2010 }}</ref>

== 不良反应 ==
本药与CD3结合时会活化T细胞，导致释放[[肿瘤坏死因子-α|肿瘤坏死因子-α]]、[[γ-干扰素|γ-干扰素]]在内的[[细胞因子|细胞因子]]，第一次注射时尤其严重。[[细胞因子释放综合征|细胞因子释放综合征]]（CRS）包括皮肤反应、[[疲勞|疲倦]]、[[发热|发热]]、[[发冷|发冷]]、[[肌肉痛|肌肉疼痛]]、[[头痛|头痛]]、[[恶心|恶心]]、[[腹泻|腹泻]]等副作用，<ref>{{Cite journal 
| pmid = 2523100 
| year = 1989 
| last1 = Abramowicz |first1 = D.| first2 = L. | first3 = M. | first4 = A. | first5 = P. | first6 = L. | first7 = J. | first8 = P. | first9 = E. 
| last10 = Toussaint | first10 = C. 
| title = Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients 
| volume = 47 
| issue = 4 
| pages = 606–608 
| journal = Transplantation 
| last2 = Schandene 
| last3 = Goldman 
| last4 = Crusiaux 
| last5 = Vereerstraeten 
| last6 = De Pauw 
| last7 = Wybran 
| last8 = Kinnaert 
| last9 = Dupont 
| doi = 10.1097/00007890-198904000-00008
| s2cid = 22740065 
}}</ref>还可能发展为[[呼吸停止|呼吸停止]]、[[心搏停止|心搏停止]]、[[突發性肺水腫|突發性肺水腫]]等急症。<ref name="DrugsCom" />为最小化CRS风险、避免其他影响病人的副作用，在注射前会给予[[糖皮质激素|糖皮质激素]]（{{link-en|甲泼尼龙|Methylprednisolone}}等）、[[对乙酰氨基酚|对乙酰氨基酚]]、[[苯海拉明|苯海拉明]]。<ref name="Bhorade2009"/>

其他不良反应包括[[白细胞减少症|白细胞减少]]、增加严重感染与[[恶性肿瘤|恶性肿瘤]]风险（免疫移植疗法常见）。已知[[神經內科|神經內科]]副作用包括{{link-en|无菌脑膜炎|aseptic meningitis}}、[[脑病|脑病]]。这些副作用可能由T细胞活化产生。<ref name="DrugsCom" />

反复用药会在病人体内形成反小鼠抗体，加快本药清除，导致{{link-en|快速免疫|tachyphylaxis}}。反复用药还会导致小鼠蛋白[[过敏性休克|过敏性休克]]，<ref name="Mutschler" />，其症状不易与CRS区分。

== 禁忌证 ==
除特殊情况外，本药禁忌证包括对小鼠蛋白过敏、未经补偿的[[心力衰竭|心力衰竭]]、未受控制的[[高血压|高血压]]、未受控制的[[癫痫|癫痫]]。本药亦不应在[[怀孕|怀孕]]或[[哺乳|哺乳]]期间使用。<ref name="Mutschler" /><ref name="DrugsCom" />

== 词源 ==
* 本药在[[世界卫生组织|世界卫生组织]]制定[[单克隆抗体命名法|单克隆抗体命名法]]前研究完成，因此其命名不遵从命名法惯例。莫罗单抗-CD3是针对CD3的小鼠单克隆抗体的缩写（''mur''ine ''mon''oclonal ''a''nti''b''ody targeting ''CD3''）。<ref name="Mutschler" />

== 来源 ==
{{reflist|2}}

{{Immunosuppressants}}

[[Category:免疫抑制剂|Category:免疫抑制剂]]
[[Category:免疫学|Category:免疫学]]
[[Category:单克隆抗体类|Category:单克隆抗体类]]